Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Epidemiological risk factors in a comparison of a Barrett Esophagus Registry (BarretNET) and a case control population in Germany.

Schmidt M, Ankerst DP, Chen Y, Wiethaler M, Slotta-Huspenina J, Becker KF, Horstmann J, Kohlmayer F, Lehmann A, Linkohr B, Strauch K, Schmid RM, Quante AS, Quante M.

Cancer Prev Res (Phila). 2020 Feb 17. pii: canprevres.0474.2019. doi: 10.1158/1940-6207.CAPR-19-0474. [Epub ahead of print]

PMID:
32066580
2.

BarrettNET-a prospective registry for risk estimation of patients with Barrett's esophagus to progress to adenocarcinoma.

Wiethaler M, Slotta-Huspenina J, Brandtner A, Horstmann J, Wein F, Baumeister T, Radani N, Gerland S, Anand A, Lange S, Schmidt M, Janssen KP, Conrad A, Johannes W, Strauch K, Quante AS, Linkohr B, Kuhn KA, Blaser R, Lehmann A, Kohlmayer F, Weichert W, Schmid RM, Becker KF, Quante M.

Dis Esophagus. 2019 Aug 1;32(8). pii: doz024. doi: 10.1093/dote/doz024.

PMID:
31329831
3.

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.

Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S, Keupp K, Kiechle M, Kölbl A, Krieger S, Kruse TA, Kvist A, Lalloo F, Larsen M, Lattimore VL, Lautrup C, Ledig S, Leinert E, Lewis AL, Lim J, Loeffler M, López-Fernández A, Lucci-Cordisco E, Maass N, Manoukian S, Marabelli M, Matricardi L, Meindl A, Michelli RD, Moghadasi S, Moles-Fernández A, Montagna M, Montalban G, Monteiro AN, Montes E, Mori L, Moserle L, Müller CR, Mundhenke C, Naldi N, Nathanson KL, Navarro M, Nevanlinna H, Nichols CB, Niederacher D, Nielsen HR, Ong KR, Pachter N, Palmero EI, Papi L, Pedersen IS, Peissel B, Perez-Segura P, Pfeifer K, Pineda M, Pohl-Rescigno E, Poplawski NK, Porfirio B, Quante AS, Ramser J, Reis RM, Revillion F, Rhiem K, Riboli B, Ritter J, Rivera D, Rofes P, Rump A, Salinas M, Sánchez de Abajo AM, Schmidt G, Schoenwiese U, Seggewiß J, Solanes A, Steinemann D, Stiller M, Stoppa-Lyonnet D, Sullivan KJ, Susman R, Sutter C, Tavtigian SV, Teo SH, Teulé A, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tornero E, Törngren T, Torres-Esquius S, Toss A, Trainer AH, Tucker KM, van Asperen CJ, van Mackelenbergh MT, Varesco L, Vargas-Parra G, Varon R, Vega A, Velasco Á, Vesper AS, Viel A, Vreeswijk MPG, Wagner SA, Waha A, Walker LC, Walters RJ, Wang-Gohrke S, Weber BHF, Weichert W, Wieland K, Wiesmüller L, Witzel I, Wöckel A, Woodward ER, Zachariae S, Zampiga V, Zeder-Göß C; KConFab Investigators, Lázaro C, De Nicolo A, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB.

Hum Mutat. 2019 Sep;40(9):1557-1578. doi: 10.1002/humu.23818.

4.

Is risk-stratified breast cancer screening economically efficient in Germany?

Arnold M, Pfeifer K, Quante AS.

PLoS One. 2019 May 23;14(5):e0217213. doi: 10.1371/journal.pone.0217213. eCollection 2019.

5.

Modifying effect of metabotype on diet-diabetes associations.

Riedl A, Wawro N, Gieger C, Meisinger C, Peters A, Rathmann W, Koenig W, Strauch K, Quante AS, Thorand B, Huth C, Daniel H, Hauner H, Linseisen J.

Eur J Nutr. 2019 May 14. doi: 10.1007/s00394-019-01988-5. [Epub ahead of print]

PMID:
31089867
6.

Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.

Engel C, Fischer C, Zachariae S, Bucksch K, Rhiem K, Giesecke J, Herold N, Wappenschmidt B, Hübbel V, Maringa M, Reichstein-Gnielinski S, Hahnen E, Bartram CR, Dikow N, Schott S, Speiser D, Horn D, Fallenberg EM, Kiechle M, Quante AS, Vesper AS, Fehm T, Mundhenke C, Arnold N, Leinert E, Just W, Siebers-Renelt U, Weigel S, Gehrig A, Wöckel A, Schlegelberger B, Pertschy S, Kast K, Wimberger P, Briest S, Loeffler M, Bick U, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

Int J Cancer. 2020 Feb 15;146(4):999-1009. doi: 10.1002/ijc.32396. Epub 2019 May 22.

PMID:
31081934
7.

Personalized Mammography Screening and Screening Adherence-A Simulation and Economic Evaluation.

Arnold M, Quante AS.

Value Health. 2018 Jul;21(7):799-808. doi: 10.1016/j.jval.2017.12.022. Epub 2018 Feb 21.

8.

Mammography Screening 2.0 - How Can Risk-Adapted Screening be Implemented in Clinical Practice?: Results of a Focus Group Discussion with Experts in the RISIKOLOTSE.DE Project.

Fürst N, Kiechle M, Strahwald B, Quante AS.

Geburtshilfe Frauenheilkd. 2018 May;78(5):506-511. doi: 10.1055/a-0603-4314. Epub 2018 Jun 4.

9.

The Association between Serum 25-Hydroxyvitamin D and Cancer Risk: Results from the Prospective KORA F4 Study.

Cheney CP, Thorand B, Huth C, Berger K, Peters A, Seifert-Klauss V, Kiechle M, Strauch K, Quante AS.

Oncol Res Treat. 2018;41(3):117-121. doi: 10.1159/000485512. Epub 2018 Feb 27.

10.

Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030.

Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, Westphalen CB, Strauch K.

Cancer Med. 2016 Sep;5(9):2649-56. doi: 10.1002/cam4.767. Epub 2016 Jun 29.

11.

Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.

Xu T, Brandmaier S, Messias AC, Herder C, Draisma HH, Demirkan A, Yu Z, Ried JS, Haller T, Heier M, Campillos M, Fobo G, Stark R, Holzapfel C, Adam J, Chi S, Rotter M, Panni T, Quante AS, He Y, Prehn C, Roemisch-Margl W, Kastenmüller G, Willemsen G, Pool R, Kasa K, van Dijk KW, Hankemeier T, Meisinger C, Thorand B, Ruepp A, Hrabé de Angelis M, Li Y, Wichmann HE, Stratmann B, Strauch K, Metspalu A, Gieger C, Suhre K, Adamski J, Illig T, Rathmann W, Roden M, Peters A, van Duijn CM, Boomsma DI, Meitinger T, Wang-Sattler R.

Diabetes Care. 2015 Oct;38(10):1858-67. doi: 10.2337/dc15-0658. Epub 2015 Aug 5.

PMID:
26251408
12.

Assessing absolute changes in breast cancer risk due to modifiable risk factors.

Quante AS, Herz J, Whittemore AS, Fischer C, Strauch K, Terry MB.

Breast Cancer Res Treat. 2015 Jul;152(1):193-197. doi: 10.1007/s10549-015-3411-6. Epub 2015 May 27.

13.

Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.

Quante AS, Whittemore AS, Shriver T, Hopper JL, Strauch K, Terry MB.

J Natl Cancer Inst. 2015 May 8;107(7). pii: djv124. doi: 10.1093/jnci/djv124. Print 2015 Jul.

14.

Assessing the goodness of fit of personal risk models.

Gong G, Quante AS, Terry MB, Whittemore AS.

Stat Med. 2014 Aug 15;33(18):3179-90. doi: 10.1002/sim.6176. Epub 2014 Apr 22.

15.

Changes in mammographic density over time in breast cancer cases and women at high risk for breast cancer.

Work ME, Reimers LL, Quante AS, Crew KD, Whiffen A, Terry MB.

Int J Cancer. 2014 Oct 1;135(7):1740-4. doi: 10.1002/ijc.28825. Epub 2014 Mar 17.

16.

Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.

Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB.

Breast Cancer Res. 2012 Nov 5;14(6):R144. doi: 10.1186/bcr3352.

17.

Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.

Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S, Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K.

J Med Genet. 2007 Feb;44(2):131-5. Epub 2006 Oct 20.

Supplemental Content

Loading ...
Support Center